Nurix Therapeutics, Inc.
NASDAQ:NRIX
Overview | Financials
Company Name | Nurix Therapeutics, Inc. |
Symbol | NRIX |
Currency | USD |
Price | 19.11 |
Market Cap | 1,353,681,693 |
Dividend Yield | 0% |
52-week-range | 7.65 - 29.56 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Arthur T. Sands M.D., Ph.D. |
Website | https://www.nurixtx.com |
An error occurred while fetching data.
About Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD